LONDON, Jan. 14, 2016 /PRNewswire/ -- Analysis of the US and European Diabetes Diagnostics Market :Constricting Reimbursement Policies Restrain Market Growth
The diabetes diagnostics markets in the United States and Europe have been in a mature stage for many years. Growth is sustained due to the high prevalence of diabetes in both regions. The segments covered in the study are self-monitoring of blood glucose (SMBG), point-of-care testing (POCT), and lab-based HbA1c testing. The emerging market of non-invasive technologies is disrupting this market space as it reduces patient pain points while providing accurate and sensitive results. Due to more hospital-centric care in the EU region, the POCT segment here experiences stronger growth than in the United States. POCT has the potential to grow the fastest due to its efficient, cost-effective solution and increasing adoption by physicians.
Key Questions this Study will Answer
-What is the diabetes diagnostics market scenario in Europe and the United States?
-How are the large exiting participants going to change this market?
-Which are the major market segments, and what are the important trends that could affect market direction?
-Who are the key market participants involved in each segment? What are their best practices in this market?
-What are the key changes in the diabetes policy system of different regions in Europe and the United States and how will they affect the market in the future?
-What is the future of the diabetes diagnostics market in Europe and the United States, and what should market participants do to succeed?
Download the full report: https://www.reportbuyer.com/product/3091082/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers